<div id="readability-page-1">Korro Bio (KRRO) shares fell following results from its early-stage clinical trial of KRRO-110, aimed at treating patients with alpha-1 antitrypsin deficiency.The trial revealed that KRRO-110 failed to meet the expected levels of functional protein after a single dose. Although the treatment did produce some functional protein, the amounts were bel...</div>

KRRO

<p>Korro Bio 的股票下跌，因為 KRRO-110 試驗未能達到預期的α-1 抗胰蛋白酶缺乏症治療所需的蛋白質水平，儘管產生了一些功能性蛋白質</p>

Korro Bio 的股票在 KRRO-110 早期試驗未能達到預期後下跌